Dihydropteroate synthase · SINGLE PROTEIN · Mycobacterium leprae (strain TN)
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-13Dihydropteroate synthase shows approved-linked disease relevance led by leprosy. 5 more disease programs remain visible in the same review block. 2 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P0C0X1. Start with leprosy, then reuse UniProt P0C0X1 as the stable protein anchor across project notes and exports.
Start with leprosy, then reuse UniProt P0C0X1 as the stable protein anchor across project notes and exports.
Dihydropteroate synthase shows approved-linked disease relevance led by leprosy. 5 more disease programs remain visible in the same review block. 2 linked drugs remain visible in the same block.
Start review with leprosy because it currently carries approved-linked support. Linked drugs include DAPSONE, SULFOXONE SODIUM. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyDihydropteroate synthase
Review this target as Dihydropteroate synthase, mapped to UniProt P0C0X1. Sequence length is 284 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Dihydropteroate synthase as ChEMBL target CHEMBL2362993, mapped to UniProt P0C0X1. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Dihydropteroate synthase is the right protein anchor across sources, using UniProt P0C0X1 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why leprosy is currently framed as approved-linked support. It currently carries 2 linked drugs in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Dihydropteroate synthase |
| Target Type | SINGLE PROTEIN |
| Organism | Mycobacterium leprae (strain TN) |
| UniProt | P0C0X1 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Dihydropteroate synthase |
| UniProt Accession | P0C0X1 |
| Component Type | Protein |
| Sequence Length | 284 aa |
Dihydropteroate synthase
Review this target as Dihydropteroate synthase, mapped to UniProt P0C0X1. Sequence length is 284 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Dihydropteroate synthase shows approved-linked disease relevance led by leprosy. 5 more disease programs remain visible in the same review block.
Start review with leprosy because it currently carries approved-linked support. Linked drugs include DAPSONE, SULFOXONE SODIUM. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.